LP
SEEL

LMR Partners’s Seelos Therapeutics, Inc. Common Stock SEEL Stock Holding History

LMR Partners’s Portfolio SEEL Stock Details SEEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-12
Closed -$48K – 1330
2022
Q3 		$48K Hold
12
– – ﹤0.01% 1103
2022
Q2 		$32K Buy
+12
New +$31.3K ﹤0.01% 1199
2021
Q2 		– Sell
-6
Closed -$120K – 1361
2021
Q1 		$120K Buy
+6
New +$70K ﹤0.01% 844

Other funds holding SEEL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GJL
Gendell Jeffrey L $7.34B AUM 183.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
UIC
Uniplan Investment Counsel Milwaukee, Wisconsin $974M AUM 21.37% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
MWM
Modera Wealth Management Westwood, New Jersey $8.34B AUM 19.68% 1-Year Est. Return
OMC
Oasis Management Company Grand Cayman, Cayman Islands $1.72B AUM 32.1% 1-Year Est. Return

LMR Partners's SEEL Position: Q4 2022 in Review

LMR Partners sold out of Seelos Therapeutics, Inc. Common Stock (SEEL) in Q4 2022, closing a stake of 12 shares — an estimated $48K sold.

LMR Partners first reported a position in SEEL in Q1 2021 and held it in 3 quarters. The position peaked at $120K in Q1 2021. 63 funds tracked by Wall St. Rank hold SEEL as of Q4 2022.

  • LMR Partners reported no remaining Seelos Therapeutics, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • LMR Partners sold 12 Seelos Therapeutics, Inc. Common Stock shares in Q4 2022, an estimated $48K.
  • LMR Partners first reported a position in Seelos Therapeutics, Inc. Common Stock in Q1 2021 and held it in 3 quarters.
  • LMR Partners's Seelos Therapeutics, Inc. Common Stock position peaked at $120K in Q1 2021.
  • 63 funds tracked by Wall St. Rank held Seelos Therapeutics, Inc. Common Stock as of Q4 2022.

Based on LMR Partners's 13F filing for Q4 2022, filed 14 Feb 2023.